Boosting photoreceptor energy to slow vision loss
A modified arrestin1 to enhance glycolysis in photoreceptors as a therapeutic approach to slowing retinal degeneration
Researchers are using a modified protein to boost energy production in rod and cone cells with the goal of slowing inherited retinal degeneration.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11249596 on NIH RePORTER |
What this research studies
This project aims to increase glycolysis (cellular energy production) specifically in your light-sensing photoreceptor cells by delivering a modified form of the protein arrestin1 called ArrGG. Scientists will test ArrGG in laboratory animal models and measure chemical energy pathways and gene activity to understand how it works. They will then apply ArrGG across several different genetic models of retinal degeneration to see if it slows photoreceptor loss broadly. The goal is a gene-agnostic approach that could benefit many kinds of inherited vision loss if the findings translate to people.
Who could benefit from this research
Good fit: People with inherited forms of retinal degeneration that affect rod and cone photoreceptors (for example, many forms of retinitis pigmentosa) would be the intended beneficiaries of this work.
Not a fit: People whose vision loss is due to non-photoreceptor causes (for example, optic nerve disease, stroke, or advanced end-stage retinal scarring with few remaining photoreceptors) would be unlikely to benefit.
Why it matters
Potential benefit: If successful, this approach could slow the loss of rods and cones across many genetic causes, preserving vision for people with inherited retinal degeneration.
How similar studies have performed: Metabolic support strategies for photoreceptors have shown benefit in animal studies, and this specific modified arrestin1 has already improved photoreceptor survival and function in at least one animal model, but human testing has not yet occurred.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Smith, W Clay — University of Florida
- Study coordinator: Smith, W Clay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.